Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2020 Filed Feb 26, 2020 21:29 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 653 | $112.17 | $73,247.01 |
DisclosureSEC source: 0001022079-20-000042 · wf-form4_158275256892243.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,516 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:40 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 5,059 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000033 · wf-form4_158224919624407.xml · derivative · entry 3 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,059 Underlying: Common Stock · 5,059 shares Expires 2030-02-18 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:40 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
GrantCommon Stock | 776 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000033 · wf-form4_158224919624407.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,619 F1 · security: Represents an award of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 · balance_after: The amount includes approximately 103 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 145,361 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000032 · wf-form4_158224910608140.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,361 Underlying: Common Stock · 145,361 shares Expires 2030-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
GrantCommon Stock | 22,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000032 · wf-form4_158224910608140.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,337 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:37 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 22,677 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000031 · wf-form4_158224903048896.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,677 Underlying: Common Stock · 22,677 shares Expires 2030-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:37 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 3,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000031 · wf-form4_158224903048896.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,455 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:35 UTC |
Davis J. E.EVP, General Diagnostics
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 40,120 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000030 · wf-form4_158224890205995.xml · derivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,120 Underlying: Common Stock · 40,120 shares Expires 2030-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:35 UTC |
Davis J. E.EVP, General Diagnostics
|
GrantCommon Stock | 6,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000030 · wf-form4_158224890205995.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,695 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:34 UTC |
Mendez Manuel O.SVP & Chief Commercial Officer
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 34,887 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000029 · wf-form4_158224883793698.xml · derivative · entry 2 Mendez Manuel O. · CIK 0001475995 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,887 Underlying: Common Stock · 34,887 shares Expires 2030-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:34 UTC |
Mendez Manuel O.SVP & Chief Commercial Officer
|
GrantCommon Stock | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000029 · wf-form4_158224883793698.xml · nonDerivative · entry 1 Mendez Manuel O. · CIK 0001475995 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,976 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:33 UTC |
GUINAN MARKExecutive Vice President & CFO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 40,120 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000028 · wf-form4_158224876751569.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,120 Underlying: Common Stock · 40,120 shares Expires 2030-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:33 UTC |
GUINAN MARKExecutive Vice President & CFO
|
GrantCommon Stock | 6,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000028 · wf-form4_158224876751569.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,169 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:32 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 26,165 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000027 · wf-form4_158224871364987.xml · derivative · entry 3 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,165 Underlying: Common Stock · 26,165 shares Expires 2030-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:32 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
GrantCommon Stock | 4,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000027 · wf-form4_158224871364987.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,538 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:30 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 34,887 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000026 · wf-form4_158224858433213.xml · derivative · entry 2 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,887 Underlying: Common Stock · 34,887 shares Expires 2030-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:30 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
GrantCommon Stock | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000026 · wf-form4_158224858433213.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 21:37 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GiftCommon Stock | 480 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000013 · wf-form4_158137060457901.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,978 F1 · shares: On February 7, 2020, the reporting person made a charitable gift of 480 shares. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:41 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 291 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000004 · wf-form4_157808769545711.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,987.831 Underlying: Common Stock · 291 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 77,865 | $66.51 Strike: $66.51 | $5,178,801.15 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · derivative · entry 8 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,865 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. F7 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 25, 2017, the second on February 25, 2018 and the final on February 25, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 65,681 | $71.17 Strike: $71.17 | $4,674,516.77 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · derivative · entry 7 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,681 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. F6 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 8,853 | $106.51 | $942,941.88 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · nonDerivative · entry 6 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,543 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. F5 · price: This transaction was executed in multiple trades at prices ranging from $106.01 to $106.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 69,003 | $105.45 | $7,276,504.36 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · nonDerivative · entry 5 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,396 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $105.00 to $106.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 7,423 | $106.51 | $790,646.00 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · nonDerivative · entry 4 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,399 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $106.00 to $106.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 58,258 | $105.46 | $6,143,772.16 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,822 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $105.00 to $105.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
Exercise / conversionCommon Stock | 77,865 | $66.51 | $5,178,801.15 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:39 UTC |
Davis J. E.EVP, General Diagnostics
|
Exercise / conversionCommon Stock | 65,681 | $71.17 | $4,674,516.77 |
DisclosureSEC source: 0001022079-20-000002 · wf-form4_157808754276203.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:32 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 1,543 | $106.52 | $164,360.36 |
DisclosureSEC source: 0001022079-20-000006 · wf-form4_157834635784180.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 32,693 | $56.12 Strike: $56.12 | $1,834,731.16 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · derivative · entry 8 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,693 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 25, 2014, the second on February 25, 2015 and the final on February 25, 2016. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 11,863 | $52.17 Strike: $52.17 | $618,833.40 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · derivative · entry 7 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,591 Underlying: Common Stock · 11,863 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 13, 2015, the second on February 13, 2016 and the final on February 13, 2017. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 500 | $107.83 | $53,915.00 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · nonDerivative · entry 5 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,458 Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 32,193 | $107.53 | $3,461,552.33 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,958 F2 · price: This transaction was executed in multiple trades at prices ranging from $106.80 to $107.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 11,863 | $107.15 | $1,271,096.72 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,151 F1 · price: This transaction was executed in multiple trades at prices ranging from $107.03 to $107.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Exercise / conversionCommon Stock | 32,693 | $56.12 | $1,834,731.16 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2019 Filed Dec 4, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Exercise / conversionCommon Stock | 11,863 | $52.17 | $618,833.40 |
DisclosureSEC source: 0001022079-19-000194 · wf-form4_157549512379632.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 16:43 UTC |
WILENSKY GAIL RDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 8,000 | $55.76 Strike: $55.76 | $446,080.00 |
DisclosureSEC source: 0001022079-19-000192 · wf-form4_157489099186199.xml · derivative · entry 4 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on May 6, 2011, the second on May 6, 2012 and the final on May 6, 2013. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 16:43 UTC |
WILENSKY GAIL RDirector
|
SaleCommon Stock | 8,000 | $107.17 | $857,352.00 |
DisclosureSEC source: 0001022079-19-000192 · wf-form4_157489099186199.xml · nonDerivative · entry 2 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,951 F1 · price: This transaction was executed in multiple trades at prices ranging from $107.05 to $107.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 16:43 UTC |
WILENSKY GAIL RDirector
|
Exercise / conversionCommon Stock | 8,000 | $55.76 | $446,080.00 |
DisclosureSEC source: 0001022079-19-000192 · wf-form4_157489099186199.xml · nonDerivative · entry 1 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:39 UTC |
MORRISON DENISE MDirector
|
GrantPhantom Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000172 · wf-form4_157004872032840.xml · derivative · entry 1 MORRISON DENISE M · CIK 0001230166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025.56 Underlying: Common Stock · 264 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:41 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 288 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000173 · wf-form4_157004884330205.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,653.571 Underlying: Common Stock · 288 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:29 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 5,000 | $55.65 Strike: $55.65 | $278,250.00 |
DisclosureSEC source: 0001022079-19-000168 · wf-form4_156892493506700.xml · derivative · entry 4 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on July 29, 2019. F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 10, 2011, the second on February 10, 2012 and the final on February 10, 2013. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:29 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
SaleCommon Stock | 5,000 | $106.00 | $530,000.00 |
DisclosureSEC source: 0001022079-19-000168 · wf-form4_156892493506700.xml · nonDerivative · entry 2 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,732 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on July 29, 2019. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 · balance_after: The amount includes approximately 53 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:29 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
Exercise / conversionCommon Stock | 5,000 | $55.65 | $278,250.00 |
DisclosureSEC source: 0001022079-19-000168 · wf-form4_156892493506700.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on July 29, 2019. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:28 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 300 | $102.77 Strike: $0.00 | $30,829.50 |
DisclosureSEC source: 0001022079-19-000157 · wf-form4_156209927861595.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,320.961 Underlying: Common Stock · 300 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:26 UTC |
MORRISON DENISE MDirector
|
GrantPhantom Stock Units · Derivative | 275 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000155 · wf-form4_156209918475466.xml · derivative · entry 1 MORRISON DENISE M · CIK 0001230166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754.92 Underlying: Common Stock · 275 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:36 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 244,565 | $52.17 Strike: $52.17 | $12,757,733.23 |
DisclosureSEC source: 0001022079-19-000149 · wf-form4_156080377688911.xml · derivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 244,565 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 13, 2015, the second on February 13, 2016 and the final on February 13, 2017. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:36 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
SaleCommon Stock | 244,565 | $100.00 | $24,456,500.00 |
DisclosureSEC source: 0001022079-19-000149 · wf-form4_156080377688911.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,049 Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:36 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 244,565 | $52.17 | $12,757,733.23 |
DisclosureSEC source: 0001022079-19-000149 · wf-form4_156080377688911.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:35 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 73,005 | $52.17 Strike: $52.17 | $3,808,305.83 |
DisclosureSEC source: 0001022079-19-000147 · wf-form4_156080369748155.xml · derivative · entry 3 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,005 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 13, 2015, the second on February 13, 2016 and the final on February 13, 2017. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:35 UTC |
GUINAN MARKExecutive Vice President & CFO
|
SaleCommon Stock | 73,005 | $100.00 | $7,300,500.00 |
DisclosureSEC source: 0001022079-19-000147 · wf-form4_156080369748155.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,017 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.